Prospective assessment of humoral and cellular immune responses to a 3rd COVID-19 mRNA vaccine dose among immunocompromised individuals.

Ghady HaidarJacob C HodgesAndrew BilderbackAmy LukanskiKelsey LinstrumBarbara PostolRachel TroyanMary K WisniewskiLindsay CoughenourAmy HeapsJana L JacobsKailey Hughes KramerCynthia Klamar-BlainJoshua KohlWendy LiangBenjamin MorrisBernard J C MacatangayUrvi M ParikhMichele D SobolewksiChristopher MusgroveMelissa D CrandallJohn MahonKatie MulveyKevin CollinsAdam C KingAlan WellsRachel ZapfMounzer AghaTami MinnierDerek C AngusJohn W Mellors

Published in: The Journal of infectious diseases (2023)

D3 significantly improves serological but not T-cell responses among immunocompromised individuals. SOT and HM patients have suboptimal responses to D3.

Keyphrases

immune response
end stage renal disease
newly diagnosed
ejection fraction
sars cov
chronic kidney disease
peritoneal dialysis
prognostic factors
dendritic cells
intensive care unit
patient reported outcomes
toll like receptor
acute respiratory distress syndrome